Chemoprevention of gastric cancer development after<i>Helicobacter pylori</i>eradication therapy in an East Asian population: Meta-analysis
Mitsushige Sugimoto, Masaki Murata, Yoshio Yamaoka
Abstract
BACKGROUND: eradication therapy reduces gastric cancer risk in patients after endoscopic and operative resection for GC, as well as in non-GC patients with atrophic gastritis. AIM: eradication therapy in an East Asian population with a high incidence of GC. METHODS: ., ≤ 5 years and > 5 years). The heterogeneity and publication bias were also measured. RESULTS: -positive controls, the eradication groups had a significantly reduced risk of GC, with a relative risk of 0.67 [95% confidence interval (CI): 0.47-0.96] for non-GC patients with atrophic gastritis and 0.51 (0.36-0.73) for patients after resection for GC in the RCTs, and 0.39 (0.30-0.51) for patients with gastritis and 0.54 (0.44-0.67) for patients after resection in cohort studies. CONCLUSION: eradication effectively reduced the risk of GC, irrespective of past history of previous cancer.